Pyrimidine derivative, and preparation method therefor and use thereof

1 . A pyrimidine derivative, wherein the pyrimidine derivative is selected from a compound represented by Formula (I), or a tautomer, an enantiomer, a diastereomer, a mesomer, a racemate, or a mixture thereof, or a pharmaceutically acceptable salt or prodrug thereof:

wherein

R 1 and R 2 are fluorine;

R 3 is hydrogen;

A is a covalent bond;

Q is a carbon atom; X is —NR 4 R 6 , wherein R 4 is hydrogen;

R 6 is methyl.

2 . A method for preparing the pyrimidine derivative according to claim 1 , wherein the method comprises:

wherein, R 1 , R 2 , R 3 , A, Q, and X have the same meanings as the corresponding groups in the pyrimidine derivative according to claim 1 ; Y is chlorine; Boc is tert-butoxycarbonyl that is an amino protecting group; TFA is trifluoroacetic acid; DCM is dichloromethane; and TFA and DCM are reagents for removing the Boc protecting group.

3 . A method for treating abnormal cell proliferative diseases in a subject, comprising a step of administrating a therapeutically effective amount of the pyrimidine derivative according to claim 1 to the subject, wherein the abnormal cell proliferative disease is leukemia.

4 . The method according to claim 3 , wherein the leukemia is selected from acute myeloblastic leukemia, chronic myelocytic leukemia, acute lymphoblastic leukemia, or chronic lymphocytic leukemia.

5 . A pharmaceutical composition, comprising the pyrimidine derivative according to claim 1 as an active ingredient and one or more pharmaceutically acceptable carriers, diluents, or excipients.

6 . The pharmaceutical composition according to claim 5 , further comprising one or more other anticancer agents as active ingredients, wherein the other anticancer agents are paclitaxel.